RPG Life Sciences, Archerchem launch Naprosyn ES combo in India
First-in-India fixed-dose combination of naproxen and esomeprazole targets long-term NSAID users. RPG Life Sciences will be the exclusive marketing and distribution partner.
What's new
- RPG Life Sciences exclusively markets Naprosyn ES, a first-in-India naproxen-esomeprazole combo.
- Product co-developed and supplied by Archerchem; RPG handles pan-India distribution.
- No financial guidance provided; launch is an incremental addition for a ₹707 cr revenue firm.
Why this matters
RPG Life Sciences, with zero debt and a 74.5% PAT drop, needs niche launches to revive momentum. Naprosyn ES addresses a specific need but without revenue guidance, it is a modest portfolio move.
What we're watching
- Whether RPG quantifies sales impact on future earnings calls.
- Supply chain execution by Archerchem given co-development.
- Any competitive responses from peers with similar combos.
The full read
RPG Life Sciences has launched Naprosyn ES, a first-in-India fixed-dose combination of naproxen and esomeprazole, in partnership with Archerchem Healthcare. RPG will handle exclusive marketing and distribution across India, while Archerchem supplies the co-developed product. The combination targets patients on long-term NSAID therapy who need gastroprotection, drawing on the strong brand recall of the legacy Naprosyn franchise. Not yet quantified. For RPG, with annual revenue of ₹707 crore and zero debt, this is an incremental addition to its branded chronic therapy portfolio. The company's recent PAT decline of 74.5% shows the need for such niche launches. But without any revenue guidance or peak sales estimates, the event remains a strategic rather than financial catalyst. The product is now available nationwide.
Questions answered
- What is Naprosyn ES and why is it significant?
- It is the first-in-India fixed-dose combination of naproxen (NSAID) and esomeprazole (PPI). The combination provides anti-inflammatory relief with gastroprotection, addressing an unmet need for patients on long-term NSAID therapy.
- What are the roles of RPG Life Sciences and Archerchem Healthcare?
- RPG Life Sciences is the exclusive marketing and distribution partner across India. Archerchem supplies the co-developed product.
- What is the addressable market for Naprosyn ES?
- The product targets patients requiring long-term NSAID therapy, such as those with osteoarthritis or rheumatoid arthritis, who are at risk of GI side effects. The exact market size is not disclosed.
- Why did the company not provide financial impact or sales targets?
- It is typical for product launches to be announced without initial projections. Analysts view this as an incremental growth driver for RPG Life Sciences, which has annual revenue of about ₹707 crore.
- How does this launch fit into RPG Life Sciences' strategy?
- The launch reinforces the company's focus on branded chronic therapies and differentiated R&D-driven products. It draws on the legacy Naprosyn brand and the company's pan-India distribution network.